Skip to main content
. 2010 Dec 27;108(4):1451–1455. doi: 10.1073/pnas.1011293108

Fig. 2.

Fig. 2.

Pravastatin induced mPGF and ameliorated the preeclampsia. (A) Hypertension induced by the placenta-specific hsFLT1 expression was ameliorated by pravastatin (PS). Pravastatin (5 μg/d) was i.p. administered into the females every day starting at the indicated day (n = 12, 14, 6, 7, and 10 for E7.5, E10.5, E13.5, E16.5, and control, respectively). Both systolic and diastolic blood pressure at E16.5 and E18.5 in the group of pravastatin treatment starting at E10.5 or earlier and LV-mPGF were significantly lower than those in the control group treated with 100 ng of p24/mL of LV-hsFLT1 (*P < 0.01). (B) The concentrations of hsFLT1, mPGF, and mVEGF circulating in the mother were measured at E18.5. (n = 3–9) (C) Wild-type pregnant female mice were given pravastatin every day starting at E7.5. The concentration of mPGF was measured at E18.5. Age-matched nonpregnant females were treated with the same protocol (n = 3–7). (D) HUVECs were cultured with statins at the indicated concentration for 24 h. The human PGF concentration in the supernatant was measured by ELISA (n = 3). There are significant differences among the values labeled with different lowercase letters in B–D (P < 0.05).